Table 4.
Multivariate analysis of prognostic factors (derivation cohort)
| Overall survival |
p value (Cox regression) |
||
|---|---|---|---|
| HR | 95% CI | ||
| Etiology | |||
| Alcohol | 1 | ||
| HCV | 0.91 | 0.74-1.12 | 0.357 |
| HBV | 1.97 | 1.38-2.82 | <0.001 |
| NASH | 0.95 | 0.50-1.81 | 0.879 |
| Other | 1.35 | 1.02-1.78 | 0.037 |
| Child-Pugh stage | |||
| A | 1 | ||
| B | 1.24 | 0.97-1.57 | 0.084 |
| C | 1.31 | 0.40-4.32 | 0.661 |
| Ascites | |||
| No | 1 | ||
| Yes | 1.57 | 1.26-1.95 | <0.001 |
| | |||
| BCLC stage | |||
| A | 1 | ||
| B | 1.09 | 0.73-1.63 | 0.661 |
| C | 1.05 | 0.68-1.61 | 0.838 |
| D | 1.61 | 0.46-5.68 | 0.462 |
| Largest tumor | |||
| <5 cm | 1 | ||
| >5 cm | 1.39 | 1.14-1.69 | 0.001 |
| Tumor extent | |||
| Unifocal | 1 | ||
| Multifocal | 1.50 | 1.22-1.84 | <0.001 |
| ECOG PS | |||
| 0 | 1 | ||
| >1 | 1.56 | 1.17-2.09 | 0.003 |
| | |||
| Macrovascular invasion | |||
| No | 1 | ||
| Yes | 1.72 | 1.35-2.20 | <0.001 |
| Extrahepatic spread | |||
| No | 1 | ||
| Yes | 1.63 | 1.24-2.13 | <0.001 |
| First-line treatment | |||
| PEI/RFA/MWA | 1 | ||
| TA(C)E | 1.40 | 1.05-1.86 | 0.021 |
| Sorafenib | 1.22 | 0.79-1.90 | 0.371 |
| Other | 2.00 | 1.49-2.68 | <0.001 |
| BSC | 3.65 | 2.65-4.94 | <0.001 |
| Low platelets + high MPV | |||
| No | 1 | ||
| Yes | 0.80 | 0.65-0.98 | 0.029 |
HCV, hepatitis C virus; HBV, hepatitis B virus; NASH, non-alcoholic steatohepatitis; BCLC, Barcelona Clinic Liver Cancer; ECOG PS, Eastern Cooperative Oncology Group performance status; PEI, percutaneous ethanol injection; RFA, radiofrequency ablation; MWA, microwave ablation; TA(C)E, transarterial (chemo)emboli-zation; BSC, best supportive care; MPV, mean platelet volume.